These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23233564)

  • 21. CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia.
    Ibrahem L; Elderiny WE; Elhelw L; Ismail M
    Blood Cells Mol Dis; 2015 Aug; 55(2):154-60. PubMed ID: 26142332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia.
    Johansson P; Eisele L; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J; Nückel H
    Leuk Res; 2010 Jul; 34(7):892-8. PubMed ID: 20353875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?
    Erikci AA; Karagoz B; Ozyurt M; Ozturk A; Kilic S; Bilgi O
    Hematology; 2009 Apr; 14(2):101-5. PubMed ID: 19298722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New prognostic markers in chronic lymphocytic leukemia.
    Moreno C; Montserrat E
    Blood Rev; 2008 Jul; 22(4):211-9. PubMed ID: 18448218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status.
    Hüttmann A; Klein-Hitpass L; Thomale J; Deenen R; Carpinteiro A; Nückel H; Ebeling P; Führer A; Edelmann J; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2006 Oct; 20(10):1774-82. PubMed ID: 16932341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Factors for Chronic Lymphocytic Leukemia.
    Chen C; Puvvada S
    Curr Hematol Malig Rep; 2016 Feb; 11(1):37-42. PubMed ID: 26748932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
    Janssens A; Van Roy N; Poppe B; Noens L; Philippé J; Speleman F; Offner F
    Eur J Haematol; 2012 Jul; 89(1):72-80. PubMed ID: 22509718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
    Zucchetto A; Benedetti D; Tripodo C; Bomben R; Dal Bo M; Marconi D; Bossi F; Lorenzon D; Degan M; Rossi FM; Rossi D; Bulian P; Franco V; Del Poeta G; Deaglio S; Gaidano G; Tedesco F; Malavasi F; Gattei V
    Cancer Res; 2009 May; 69(9):4001-9. PubMed ID: 19383907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: correlation with CD38 expression.
    Ottaggio L; Viaggi S; Zunino A; Zupo S; Rossi E; Spriano M; Abbondandolo A; Ferrarini M
    Haematologica; 2003 Jul; 88(7):769-77. PubMed ID: 12857555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia.
    Siddon AJ; Rinder HM;
    Am J Clin Pathol; 2013 Jun; 139(6):708-12. PubMed ID: 23690112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Soma LA; Craig FE; Swerdlow SH
    Hum Pathol; 2006 Feb; 37(2):152-9. PubMed ID: 16426914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
    Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
    Amaya-Chanaga CI; Rassenti LZ
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
    Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.
    Aydin S; Grabellus F; Eisele L; Möllmann M; Hanoun M; Ebeling P; Moritz T; Carpinteiro A; Nückel H; Sak A; Göthert JR; Dührsen U; Dürig J
    Eur J Haematol; 2011 Jul; 87(1):10-9. PubMed ID: 21692849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.
    Shanafelt TD; Witzig TE; Fink SR; Jenkins RB; Paternoster SF; Smoley SA; Stockero KJ; Nast DM; Flynn HC; Tschumper RC; Geyer S; Zent CS; Call TG; Jelinek DF; Kay NE; Dewald GW
    J Clin Oncol; 2006 Oct; 24(28):4634-41. PubMed ID: 17008705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
    Zucchetto A; Bomben R; Dal Bo M; Sonego P; Nanni P; Rupolo M; Bulian P; Dal Maso L; Del Poeta G; Del Principe MI; Degan M; Gattei V
    J Cell Physiol; 2006 May; 207(2):354-63. PubMed ID: 16331666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.